Zacks: Analysts Anticipate Rockwell Medical Inc (NASDAQ:RMTI) Will Announce Earnings of -$0.12 Per Share

Brokerages predict that Rockwell Medical Inc (NASDAQ:RMTI) will announce earnings per share (EPS) of ($0.12) for the current quarter, Zacks reports. Two analysts have made estimates for Rockwell Medical’s earnings, with estimates ranging from ($0.12) to ($0.11). Rockwell Medical reported earnings per share of ($0.15) in the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The firm is expected to announce its next earnings report on Thursday, March 12th.

According to Zacks, analysts expect that Rockwell Medical will report full year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.59) to ($0.56). For the next year, analysts anticipate that the business will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.44) to ($0.20). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Rockwell Medical.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Monday, November 11th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The business had revenue of $15.41 million for the quarter, compared to the consensus estimate of $15.40 million. Rockwell Medical had a negative return on equity of 139.38% and a negative net margin of 57.77%.

RMTI has been the topic of several research analyst reports. Zacks Investment Research downgraded Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Piper Jaffray Companies dropped their price target on Rockwell Medical from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Rockwell Medical in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $9.33.

A number of institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its stake in Rockwell Medical by 12.2% during the 3rd quarter. California State Teachers Retirement System now owns 96,377 shares of the company’s stock valued at $266,000 after purchasing an additional 10,490 shares during the last quarter. State Street Corp boosted its stake in shares of Rockwell Medical by 7.5% in the third quarter. State Street Corp now owns 1,079,852 shares of the company’s stock worth $2,980,000 after buying an additional 74,883 shares during the last quarter. Gabelli Funds LLC boosted its stake in shares of Rockwell Medical by 31.0% in the third quarter. Gabelli Funds LLC now owns 21,121 shares of the company’s stock worth $58,000 after buying an additional 5,000 shares during the last quarter. Dillon & Associates Inc. purchased a new stake in shares of Rockwell Medical in the third quarter worth about $34,000. Finally, Jag Capital Management LLC boosted its stake in shares of Rockwell Medical by 19.4% in the third quarter. Jag Capital Management LLC now owns 30,750 shares of the company’s stock worth $85,000 after buying an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 21.41% of the company’s stock.

Rockwell Medical stock traded down $0.06 during trading hours on Wednesday, hitting $2.09. 235,800 shares of the stock traded hands, compared to its average volume of 345,819. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.27 and a quick ratio of 2.98. The firm’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.94. The stock has a market capitalization of $134.64 million, a price-to-earnings ratio of -4.45 and a beta of 1.45. Rockwell Medical has a 1 year low of $1.81 and a 1 year high of $6.88.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.

Featured Article: How to invest using market indexes

Get a free copy of the Zacks research report on Rockwell Medical (RMTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.